The risk of early relapse is increased when radiotherapy is omitted in patients with stage I/II Hodgkin lymphoma whose PET scan findings are negative, according to an interim trial analysis.
Patients with terminal forms of leukemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects.
The use of radioimmunotherapy treatment in patients with newly diagnosed follicular lymphoma has been investigated in a new study.
Idelalisib demonstrates antitumor activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
The FDA has accepted the Supplemental New Drug Application and granted it Priority Review for the expanded use of Lymphoseek Injection for sentinel lymph node detection in patients with head and neck cancer.
The FDA has accepted for review Gilead Sciences’ New Drug Application for idelalisib for the treatment of indolent non-Hodgkin lymphoma.
Gene expression profile of lymph nodes closest to the tumor may reveal prognosis.
A phase 1b/2, open-label study finds a low rate of severe adverse events as well as promising efficacy data.
Early stem cell transplants may be beneficial for some patients with NHL, but it’s not been shown to improve overall survival.
Long-term rituximab maintenance prolongs PFS in follicular lymphoma.
